Evidence for the Treatment of Osteoporosis with Vitamin D in Residential Care and in the Community Dwelling Elderly
Table 1
Characteristics of residential studies.
Duration
Treatment
Dose (IU)
Regimen
Number
Female (%)
Age mean (SD)
Vitamin D (nmol/L)# mean (SD) or median (IQR)
Ca+ intake (mg/day) mean (SD) or median (IQR)
Chapuy
3 years
All
3270
100
84 (6)
NA
513
D3
800 daily
CaD
1634
84 (6)
40 (28)
511 (172)
P
P
1636
84 (6)
33 (23)
514 (158)
Decalyos II
2 years
All
583
100
85 (7)
557.7
D3
800 daily
CaD fixed CaD split
393
85 (7) 85 (7)
21 (13) 23 (17)
565 (230) 551 (238)
P
P
190
86 (8)
23 (17)
556 (246)
Flicker
2 years
All
625
95
83
25–90
NA
D2
10000 weekly
CaD
312
84 (8)
NA
NA
P
CaP
313
83 (9)
NA
NA
Lips-combined
Max. 3.5 years
All
2578
74
80 (6)
NA
D3
400 daily
D
1291
80 (6)
27 19–36
NA
P
P
1287
80 (6)
26 19–37
NA
Ooms
2 years
All
348
100
D3
400 daily
D
177
80 (6)
68 48–90
876 638–1101
P
P
171
81 (6)
63 48–93
859 644–1099
Meyer
2 years
All
1144
75
85 (7)
D3
440 daily
D
569
84 (7)
47 (26)
456 (196)
P
P
575
85 (7)
51 (33)
446 (196)
Heikinheimo residential
Range 2–5 years
All
320
82
NA
NA
NA
D2
150000–300000 yearly*
D
142
79
NA
NA
P
P
178
79
NA
NA
Lyons
3 years
All
3440
76
84 (8)
NA
NA
D2
100000 4 monthly
D
1725
76
84 (8)
NA
NA
P
P
1715
77
84 (8)
NA
NA
IM treatment. Changed to 1000 IU daily during the course of the study.
#Divide by 2.5 for ng/mL. IU: international units; D2: ergocalciferol; D3: cholecalciferol; D: vitamin D; CaD: calcium and vitamin D; Ca: calcium; P: placebo or control; NA: not available.
